A valuable weapon in war against drug-resistant superbugs: Antibiotic offers hope
Tests show that drug is effective against the same kind of chronic bacterial infections that have killed hospital patients
Steve Connor is the Science Editor of The Independent. He has won many awards for his journalism, including five-times winner of the prestigious British science writers’ award; the David Perlman Award of the American Geophysical Union; twice commended as specialist journalist of the year in the UK Press Awards; UK health journalist of the year and a special merit award of the European School of Oncology for his investigative journalism. He has a degree in zoology from the University of Oxford and has a special interest in genetics and medical science, human evolution and origins, climate change and the environment.
Wednesday 13 November 2013
A new kind of antibiotic that causes microbes to digest themselves has been developed by scientists who believe it could become a valuable weapon in the war against drug-resistant “superbugs”.
Laboratory tests show that the drug is effective against persistent strains of the Staphylococcus bacterium and is able to cure laboratory mice of the same kind of chronic bacterial infections that have killed hospital patients.
Kim Lewis of Northeastern University in Boston, Massachusetts, said that the drug, called acyldepsipeptide (ADEP4), works by activating an enzyme within the dormant “persister” cells of the bacteria, which causes these hardened microbial cells to self-digest.
“Persister cells don’t grow. They shut down their metabolism and in order for antibiotics to work against bacteria, the microbes must grow. ADEP4 essentially forces the cells to self-digest. The compound has an ability to sterilise an infection,” Dr Lewis said.
ADEP4 activates a protease enzyme that breaks down proteins within bacteria. However, resistance soon develops against the drug, which is why it was abandoned by the drug industry in the 1980s as a possible antibiotic, he said.
The study, published in the journal Nature, demonstrated however that when ADEP4 is used in conjunction with a conventional antibiotic, such as rifampicin, it is very effective at ridding an infection of the persister cells that are often left untouched by the treatment.
“They become susceptible to killing by any antibiotic essentially. One of the major causes of drug resistance is a large, lingering population of pathogens which happens in patients with chronic infections,” Dr Lewis said.
“If you can rapidly sterilise and get rid of that large population, you then get rid of an enormous source of resistance acquisition,” he said.
Kenn Gerdes of Newcastle University and Hanne Ingmer of the University of Copenhagen said in an accompanying article in Nature that the results were “remarkable” and offer hope for a new way of tackling resistant bacterial infections.
“This growing body of results generates hope that antibiotics for the treatment of persistent infections will be available in the future,” they say.
- 1 Michael Brown shooting: Amnesty International sends team within US for first time as National Guard deployed
- 2 Greggs Google fail: bakery falls afoul of search engine's algorithms with 'unofficial' logo
- 3 Is this the end of apps? New research says a third of us don't bother to download
Isis threat: Cameron wants an alliance with Iran
Crisis? What crisis? A visiting US doctor gives the NHS a rave review
Ukip MEP calls for reintroduction of death penalty on fiftieth anniversary of last deaths
Russell Brand calls for Israel boycott: Comedian urges big businesses that 'facilitate the oppression of people in Gaza' to pull funding
Michael Brown shooting: Chaos erupts on the streets of Ferguson after autopsy shows teenager was shot six times – twice in the head
World peace? These are the only 11 countries in the world that are actually free from conflict
£30000 - £33000 per annum + Benefits + Bonus: Harrington Starr: Junior DBA (SQ...
£60000 - £75000 per annum + BONUS + BENEFITS: Harrington Starr: Business Anal...
£60000 - £90000 per annum + Bonus: Harrington Starr: Global leading Energy Tra...
£40000 - £60000 per annum + BONUS + BENEFITS: Harrington Starr: CXL, Triple Po...